Edwards Lifesciences will not acquire JenaValve, updates FY26 guidance

Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients. In light of this update, Edwards is revising its full-year 2026 adjusted EPS guidance to $2.90-$3.05 from earlier guidance of $2.80-$2.95. FY26 consensus $2.87.